Defining stage in mucinous tumours of the appendix with peritoneal dissemination: the importance of grading terminology: systematic review

L. Martín-Román1,2, P. Lozano1,2, W. Vásquez1,2, N. Palencia1, Y. Gómez3, M. J. Fernández-Aceñor3 and L. González-Bayón1,2,*

1 Peritoneal Carcinomatosis Unit, Department of General and Digestive Surgery, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2 Department of Surgery, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain
3 Department of Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

*Correspondence to: Peritoneal Carcinomatosis and Complex Pelvis Unit, Department of General and Digestive Surgery, Hospital General Universitario Gregorio Marañón, Calle del Dr Esquerdo, 46, 28007, Madrid, Spain (e-mail: lgbayon@salud.madrid.org)

Abstract

Background: Mucinous appendiceal neoplasms with peritoneal dissemination (PD) show a wide spectrum of clinical behaviour. Histological grade has been correlated with prognosis, but no universally accepted histological grading has been established. The aim of this systematic review was to provide historical insight to understand current grading classifications, basic histopathological features of each category, and to define which classification correlates best with prognosis.

Methods: MEDLINE and the Cochrane Library were searched for studies that reported survival across different pathological grades in patients with mucinous neoplasm of the appendix with PD treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PRISMA guidelines were followed.

Results: Thirty-eight studies were included. Ronnett’s classification was the most common (9 studies). Classifications proposed by the Peritoneal Surface Oncology Group International (PSOGI) (6 studies) and the seventh or eighth edition of the AJCC (7 studies) are gaining in popularity. Nine studies supported a two-tier, 12 a three-tier, and two a four-tier classification system. Three studies demonstrated that acellular mucin had a better prognosis than low-grade pseudomyxoma peritonei in the PSOGI classification or M1bG1 in the eighth edition of the AJCC classification. Four studies demonstrated that the presence of signet ring cells was associated with a worse outcome than high-grade pseudomyxoma peritonei in the PSOGI classification and M1bG2 in the eighth edition of the AJCC.

Conclusion: There is a great need for a common language in describing mucinous neoplasms of the appendix with PD. Evolution in terminology as a result of pathological insight turns the four-tiered PSOGI classification system into a coherent classification option.

Introduction

Primary appendiceal tumours have a low incidence of 2.6 per million people per year1,2. Epithelial tumours of the appendix are subdivided into benign lesions (adenomas, serrated polyps), mucinous neoplasms, invasive mucinous adenocarcinoma, non-mucinous adenocarcinoma, goblet cell adenocarcinoma, and appendiceal carcinoids (well differentiated neuroendocrine tumours). Recent reports3,4 based on the Surveillance, Epidemiology, and End Results (SEER) database have stated that mucinous tumours are the most frequent histological subtype. This review focuses on this last subtype.

Mucinous tumours of the appendix exhibit a tendency towards transcelomic spread into the peritoneum causing peritoneal mucinous carcinomatosis (PMCA) or a mucinous ascites referred to as pseudomyxoma peritonei (PMP). The definition of PMP is nowadays limited to the clinical indolent entity characterized by the grossly evident diffuse intra-abdominal accumulation of mucus following the redistribution phenomenon5. It is a malignant condition most frequently originating from the appendix, but it should not be used as a histological diagnostic entity. Mucinous appendiceal tumours with peritoneal dissemination (PD) show a wide spectrum of clinical behaviour ranging from slow-growing lesions with no recurrence after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) to highly aggressive adenocarcinomas associated with decreased overall survival (OS). Several studies6–11 have identified histological grade as one of the most important prognostic factors. However, no definitive grading terminology has been established despite several past attempts. This has resulted in the existence of several confusing and overlapping terminologies across the literature, which makes it difficult to develop management protocols and compare outcomes across different series.

The aim of this systematic review was to provide sufficient historical insight to understand current grading classifications, basic histopathological descriptions of each category, and to define the classification that correlates best with prognosis.
Methods
The systematic review was done according to PRISMA guidelines12.

Data search
The PICO data search strategy was employed. The following Medical Subject Heading (MeSH) terms were used for each category: under the P (population) category—‘pseudomyxoma peritonei’, ‘appendiceal mucinous neoplasms’, ‘appendix cancer’, ‘appendiceal neoplasms’, ‘peritoneal dissemination’, ‘acellular mucin’, and ‘signet ring cells’; under the I (intervention) category—‘cytoreductive surgery’, ‘intrapерitoneal injections’, and ‘cytoreductive surgery and hyperthermic intraperitoneal chemotherapy’; under the C (comparison) category—‘pathology’ and ‘grading pathology’; and under the O (outcome) category—‘classification’, ‘prognosis’, ‘recurrence’, ‘disease free survival’, ‘survival analysis’, and ‘survival rate’. The literature was reviewed throughout MEDLINE and Cochrane Library platforms. MeSH terms were combined with ‘AND’/‘OR’. The detailed search strategy is shown in Appendix S1. Only studies published in English were considered and an abstract had to be available.

Classification schemes, consensus guidelines, and studies that influenced grading criteria were retrieved manually from reference lists. Some of these did not meet the eligibility criteria, but were included because of their historical relevance7,9,13.

Eligibility criteria
Studies that dealt with patients with PD from mucinous tumours of the appendix treated with CRS/HIPEC and reported OS or disease-free survival (DFS) with reference to pathological grading were included. The additional inclusion of other primary tumours of the appendix or even other gastrointestinal tumours (such as colorectal lesions) with PD was not a criterion for exclusion as survival results for tumours of the appendix with PD were reported separately. Results had to be reported independently in the form of median OS or 5-year OS rates, and/or median DFS or 5-year DFS rates, for each histological grade of the peritoneal implants. At least two different histological grades of peritoneal implants had to be compared in univariable or multivariable analysis.

No selection based on how pathological grade was assigned. In some studies, pathology slides were reviewed, whereas in others the classification was based on pathology reports or on information coded into large databases. No selection was made with respect to the classification system used to grade the pathology of peritoneal implants (Ronnett’s, WHO, Peritoneal Surface Oncology Group International (PSOGI) or AJCC). The search included reports from January 2000 to February 2020.

Case reports and reviews were excluded. Other exclusion criteria were: fewer than 100 patients, no CRS/HIPEC treatment, and exclusive analysis of primary appendiceal lesions without PD. Studies that centred on ovarian involvement and the differential diagnosis between ovarian cancer and PMP of appendiceal origin were also excluded.

Study selection
Two authors assessed the titles and abstracts for eligibility throughout the search and reference lists, followed by full-text screening. Whether studies met the inclusion criteria was discussed between the two authors before inclusion.

The studies included were retrospective case–control studies. Consensus and staging guidelines (5) and retrospective studies (3) not fully meeting eligibility criteria were extracted manually from reference lists, of which one7 was published before the time interval set for the search.

Each article was analysed systematically. Initially, a search was made for the histology of the primary appendiceal tumour, then for the histopathological grading of the peritoneal implants. The pathological description provided for each grade was recorded. Next, it was identified whether a two, three- or four-tiered classification system was supported. Finally, median OS and/or DFS rates for each tier were recorded based on results of survival analysis.

Results
A total of 849 records were identified, of which 98 were screened fully by abstract or full-text screening. Reasons for exclusion are shown in Fig. 1. Finally, 38 studies that met the eligibility criteria were included, 308–11,14–39 of which are summarized in Table 1. Classification systems30–49, and two observational studies7,13 were not included in Table 1. Most relevant classification systems are summarized in Table 2.

Initial classification systems
Several study groups have aimed to distinguish and define relevant prognostic groups in patients with PMP.

In 1995, Ronnett and colleagues7,8 studied 109 peritoneal lesions defined as PMP and identified three different histological groups based on the pathological characteristics of primary and peritoneal lesions. Primary tumours were classified into: adenoma (villic adenoma or cystadenoma), ruptured adenoma, and adenocarcinoma (invasion of the muscularis accompanied by stromal response) with or without signet ring cells (SRCs). Peritoneal lesions were subdivided into: disseminated peritoneal adenomucinosis (DPAM), PMCA, and peritoneal mucinous carcinomatosis with intermediate or discordant features (PMCA-I/D). Peritoneal lesions in DPAM were defined as scant strips of simple or focally proliferative epithelium with minimal to moderate cytological atypia and no significant mitotic activity with abundant extracellular mucin. A primary appendiceal adenoma was found in 57 per cent of patients with DPAM. Peritoneal lesions in FMCA consisted of a larger component of proliferative mucinous epithelium-forming glands, or organized in nests or individual cells, SRCs were included in this group. The cells demonstrated marked cytological atypia and architectural complexity. Most cases of PMCA were found alongside a primary appendiceal or colonic adenocarcinoma. In intermediate PMCA, there were focal areas of mucinous carcinoma immersed within areas resembling DPAM where primary lesions could be well differentiated mucinous adenocarcinomas or adenomas. Cases of discordant PMCA had peritoneal lesions with features of mucinous carcinoma with or without SRC differentiation originating from an atypical adenoma of the appendix with high-grade dysplasia or an intramuscosal adenocarcinoma (Table 2).

Ronnett et al.8 identified three prognostic groups. Patients with DPAM had a significantly more favourable prognosis than those with PMCA-I/D or PMCA (5-year OS 75 per cent versus 50 and 14 per cent respectively; P = 0.001). They also concluded that PMP should not be used as a pathological diagnostic term but rather as a clinical entity. They argued that DPAM was a benign peritoneal lesion and were against using well differentiated mucinous carcinoma to refer to these lesions. However, they included 13 tumours of colonic origin, one of small bowel origin, and 7 of unknown origin (colonic versus appendiceal).
Misdraji and co-workers\(^9\) reviewed 107 appendiceal mucinous tumours, of which 53 had PD. SRCs were excluded from this study. They introduced the term low-grade appendiceal mucinous neoplasm (LAMN) into the literature to refer to primary appendicular lesions lacking infiltrative invasion of the appendicular wall that could, however, disseminate through the peritoneal cavity. LAMNs demonstrated low-grade cytological atypia (nuclear enlargement, scarce nuclear stratification, and rare mitotic figures) and minimal architectural complexity (uniform, flat epithelial proliferation forming small papillary excrescences/outgrowths). On the other hand, mucinous adenocarcinomas of the appendix (MACAs) were defined by infiltrative invasion of the appendicular wall with high cytological atypia (full-thickness nuclear stratification, vesicular nuclei with prominent nucleoli, and brisk mitotic figures). When PD was present, the terms LAMNs involving the peritoneum and MACAs involving the peritoneum were used (Table 2). Misdraji et al. defined a two-tiered system in which LAMNs involving the peritoneum had a better prognosis than MACAs involving the peritoneum (5-year OS 86 versus 44 per cent, \(P = 0.04\)).

In 2006, Bradley and colleagues\(^10\) revised the histology of 101 cases of PMP originating from the appendix, and reclassified them according to Ronnett’s DPAM, PMCA-I, and PMCA. Appendiceal tumours were evaluated independently and classified into adenomas/LAMNs or adenocarcinomas. The tumours classified as DPAM, which originated from adenomas in Ronnett’s classification, were associated with a primary LAMN, whereas PMCA-I (high-grade atypia and/or SRCs) were associated with moderate or poorly differentiated appendiceal adenocarcinomas. There was no significant difference in 5-year OS between the DPAM group (61.8(9.2) per cent) and the PMCA-I group (68.2(12.2) per cent). The PMCA group did, however, have significantly worse 5-year OS (38 per cent; \(P = 0.004\)). Therefore, Bradley and co-workers supported a two-tiered classification system whereby SRCs were included in the PMCA subgroup. They advocated use of the terms low-grade mucinous carcinoma peritonei (MCP-L) instead of Ronnett’s DPAM and high-grade mucinous carcinoma peritonei (MCP-H) for Ronnett’s PMCA.

Pai et al.\(^17\) suggested that both primary tumours and peritoneal implants should be described using the following scheme: presence of neoplastic epithelium, degree of cytologic atypia (low versus high), architectural complexity (simple versus complex), and presence of invasion. The presence of SRCs was considered to indicate high-grade disease. They proposed a grading system based on cytological features and disease extension. The term mucinous adenoma was given to low-grade proliferative lesions confined to the appendix. A three-tiered classification was proposed for tumours with PD. Low-grade mucinous neoplasm with low risk of recurrence was proposed to refer to a low-grade

---

**Fig. 1 Flow chart showing selection of studies for review**

OS, overall survival; DFS, disease-free survival; CRS, cytoreductive surgery.
Table 1 Comparison of oncological results according to the different histological grades

| Reference       | No. of patients | Histological classification | Histological nomenclature          | OS (%)  | DFS (%) | Impact of histology on OS and DFS in multivariable analysis |
|-----------------|-----------------|-----------------------------|-----------------------------------|---------|---------|-----------------------------------------------------------|
| Ronnett et al.  | 109             | Ronnett’s classification    | DPAM (65) PMCA-I (11) PMCA (30)   | 75†     | 50†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | n.a.                                                      |
| Misraji et al.  | 107             | LAMN with PD (49) MACA with PD (4) MCP-I (78) MCP-I-H (23) | 86†     | 44†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | n.a.                                                      |
| Bradley et al.  | 101             | Ronnett’s classification    | DPAM (55) PMCA-I (18) PMCA (29) HG non-mucinous (8) | 77.4†   | 40†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | OS; n.s.                                                  |
| Stewart et al.  | 110             | Ronnett’s classification    | DPAM (55) PMCA-I (18) PMCA (29) HG non-mucinous (8) | 77.4†   | 35†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | OS: increased risk of death in PMCA-I (HR 3.4; P < 0.001) and PMCA (HR 10.4; P < 0.001) versus DPAM |
|                 |                 |                             |                                   |         |         | DFS: increased risk of recurrence in PMCA-I (HR 1.9; P < 0.05) and PMCA (HR 4.1; P < 0.01) versus DPAM |
| Smeenk et al.   | 103             | Ronnett’s classification    | DPAM - PMCA-I - PMCA              | 77.4†   | 40†     | n.a.                                                      |
| Elias et al.    | 105             | Ronnett’s classification    | DPAM - PMCA-I - PMCA              | n.a.    | 35.3†   | CYTLOGICAL FEATURES ASSOCIATED WITH DECREASED OS: EXTRAAPPENDICEAL NEOPLASTIC EPITHELIUM VERSUS LG-LR (AM) (P < 0.001) and HG VERSUS LG CYTOTOLOGY (P = 0.001) |
| Pai et al.      | 116             | LG-LR LG-HR Mucinous ADC    | 100†                              | 88†     | 20†     | CYTLOGICAL FEATURES ASSOCIATED WITH DECREASED DFS: EXTRAAPPENDICEAL NEOPLASTIC EPITHELIUM VERSUS LG-LR (AM) (P < 0.001) and HG VERSUS LG CYTOTOLOGY (P = 0.05) |
|                 |                 |                             |                                   |         |         | CYTLOGICAL FEATURES ASSOCIATED WITH DECREASED DFS: EXTRAAPPENDICEAL NEOPLASTIC EPITHELIUM VERSUS LG-LR (AM) (P < 0.001) and HG VERSUS LG CYTOTOLOGY (P = 0.001) |
| Elias et al.    | 301             | Ronnett’s classification    | DPAM (136) PMCA-I (71) PMCA (59)  | 85†     | 84†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | OS: decreases risk of death in DPAM + PMCA-I versus PMCA (HR 0.33; P = 0.02) |
| Chua et al.     | 2298            | Ronnett’s classification    | DPAM (1419) PMCA-I (140) PMCA (700) | 82†     | 79†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | OS: increased risk of death in PMCA versus DPAM + PMCA-I (HR 1.69; P < 0.001) |
|                 |                 |                             |                                   |         |         | DFS: increased risk of recurrence in PMCA versus DPAM + PMCA-I (HR 1.9; P < 0.001) |
|                 |                 |                             |                                   |         |         | DFS: increased risk of recurrence in PMCA versus DPAM + PMCA-I (HR 1.9; P < 0.001) |
| Carr et al.     | 274             | 4th edition WHO            | LG-PMP (207) HG-PMP (50)          | 84†     | 69†     | n.a.                                                      |
|                 |                 |                             |                                   |         |         | OS: increased risk of death in G2 (HR 1.56) and G3 (HR 5.15) versus G1 |
| Overman et al.  | 2469            | 7th edition AJCC           | MAC (1375, stage IV) G1, G2, G3 SRCC (234, stage IV) | 71†, 51†, 0† | 71†, 51†, 0† | n.a.                                                      |

(continued)
| Reference     | No. of patients | Histological classification | Histological nomenclature | OS (%)† | DFS (%)† | Impact of histology on OS and DFS in multivariable analysis |
|---------------|----------------|-----------------------------|---------------------------|---------|----------|----------------------------------------------------------|
| Shetty et al. | 211            | PMP 1 (80)                  |                           | 85.7†   | n.a.     | DFS: increased risk of recurrence in G2 (HR 1.73) and G3 (HR 1.93) versus G1 |
|               |                | PMP 2 (75)                  |                           | 63.1†   |          | OS: increased risk of death in G2 (HR 2.7) and G3 (HR 5.1) versus G1 (P = 0.008) |
|               |                | PMP 3 (50)                  |                           | 32.2†   |          |                                                          |
| Davison et al.| 151            | 7th edition AJCC            | PMP1                      | 91†     | n.a.     |                                                          |
|               |                |                             | PMP2                      | 61†     |          |                                                          |
|               |                |                             | PMP3                      | 23†     |          |                                                          |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
|                |                |                             |                           | G1 versus G2 | (P < 0.001) | DFS: increased risk of recurrence in G2 (HR 1.73) and G3 (HR 1.93) versus G1 |
|                |                |                             |                           | G2 versus G3 | (P = 0.07) | OS: increased risk of death in G2 (HR 2.7) and G3 (HR 5.1) versus G1 (P = 0.008) |
| Jimenez et al.| 202            | Ronnett’s classification    | DPAM (77)                 | 83†     | 58†      | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | PMCA (125)                | 41†     | 34†      |                                                          |
|               |                |                             |                           | (P < 0.001) |          |                                                          |
| Shaib et al.  | 165            | Ronnett’s classification    | DPAM (60)                 | 98 months§ | n.a.     | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | PMCA-I/D (15)             | 39 months§ |          |                                                          |
|               |                |                             | PMCA (88)                 | 28 months§ |          |                                                          |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
| Ihemelandu et al. | 494 | PMCA (361)                  | 38†                      | n.a.     |          | OS: increased risk of death in PMCA-S versus PMCA (HR 1.4; P = 0.003) |
|               |                |                             | PMCA-S (80)               | 22†     |          |                                                          |
|               |                |                             | PMCA-A (53)               | 15†     |          |                                                          |
| Milovanov et al. | 208 | Ronnett’s classification and 7th edition AJCC | DPAM (84)    | 88†     | 71†      | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | IVA PMCA (47)            | 67†     | 43†      |                                                          |
|               |                |                             | IVB PMCA (77)            | 27†     | 15†      |                                                          |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
|                |                |                             | DPAM versus PMCA IVA     | 83†     | 58†      | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|                |                |                             |                           | (P = 0.002) |          |                                                          |
| Asare et al.  | 3105 stage IV  | 7th edition AJCC            | G1                        | 56.7†   | n.a.     | OS: increased risk of death in G2 (HR 1.92) and G3 (HR 3.71) versus G1 (P < 0.001) |
|               |                |                             | G2                        | 31.5†   |          |                                                          |
|               |                |                             | G3                        | 11.3†   |          |                                                          |
| Grotz et al.  | 265            | 7th edition AJCC            | G1 (201)                  | 94†     | 66†      | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | AM (34)                   | 100†    | 93†      |                                                          |
|               |                |                             | G2 (45)                   | 71†     | 21†      |                                                          |
|               |                |                             | G3 (19)                   | 21†     | 0†       |                                                          |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
| Huang et al.  | 444            | PSOGI classification        | AM (44)                   | 95.2†   | n.a.     | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | DPAM (232)                | 83†     |          |                                                          |
|               |                |                             | PMCA (119)                | 47†     |          |                                                          |
|               |                |                             | PMCA-S (49)               | 12†     |          |                                                          |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
|                |                |                             |                           | n.r.§   | 34.4 months§ | DFS: increased risk of recurrence in LG-MCP (HR 9.8; P = 0.025) and in HG-MCP (HR 24.6; P = 0.002) versus AM |
|                |                |                             |                           | (P < 0.001) |          |                                                          |
| Reghunathan et al. | 197 | PSOGI classification        | AM (33)                   | n.a.    |          | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | LG-MCP (114)              | 34.4 months§ |          |                                                          |
|               |                |                             | HG-MCP (44)               | (P < 0.001) |          |                                                          |
| Baratti et al. | 265            | PSOGI classification        | AM (26)                   | 89.3†   | n.a.     | OS: increased risk of death in PMCA versus DPAM (HR 3.53; P = 0.007) |
|               |                |                             | LG-PMP (197)              | 77.5†   |          |                                                          |
|               |                |                             | HG-PMP (38)               | 51†     |          |                                                          |
|               |                |                             | SRC-PMP (4)               | 0†      |          |                                                          |

(continued)
mucinous epithelial proliferation with acellular mucin outside the appendix. The term low-grade mucinous neoplasm with high risk of recurrence was chosen for the same cytologically bland proliferation associated with extra-appendiceal neoplastic epithelium. When invasion was present, the term mucinous adenocarcinoma was chosen for both primary and disseminated disease. The presence of extra-appendiceal neoplastic epithelium (*P = 0.006*) and high-grade cytology (*P = 0.001*) was associated with decreased OS.

**WHO and seventh edition of AJCC classification systems**

In an attempt to unify the diagnostic terminology surrounding appendiceal mucinous tumours, both the fourth edition of the
| Reference/classification | Stage of disease | Type | Histological nomenclature | Key histological features |
|--------------------------|------------------|------|---------------------------|--------------------------|
| Ronnett et al. 7 | Primary tumours | Benign lesions | Villous adenoma | Adenomatous epithelium with villous architecture confined to mucosa |
|                        |                  |      | Cystadenoma | Adenomatous epithelium without villous architecture confined to mucosa of a dilated appendix |
|                        |                  |      | Dilated/ruptured adenoma | Glands or strips of adenomatous epithelium within wall or on serosa of a dilated or ruptured appendix without stromal response Dissecting mucin or epithelium extending through wall of appendix |
|                        | Invasive lesions | Adenocarcinoma | Mucinous adenocarcinoma with SRCs | Neoplasms with glandular and SRC differentiation, with or without neuroendocrine features that showed marked cytological atypia and muscularis invasion |
|                        | Peritoneal implants | DPAM | PMCA I/D | Features of DPAM with focal areas of carcinoma +/- SRCs |
|                        |                  |      | PMCA | Abundant proliferative epithelium, glands, nests or individual cells including SRCs, demonstrating marked cytological atypia and mitotic activity |
| Misdrangi et al. 9 | Primary mucinous tumours | Benign lesions | LAMN | Low-grade cytological atypia (nuclear enlargement, scarce nuclear stratification, and rare mitotic figures) and minimal architectural complexity (uniform, flat epithelial proliferation forming small papillary excrescences). No infiltrative invasion of appendiceal wall |
|                        | Peritoneal implants | LAMN with peritoneal dissemination | MACA | High cytological atypia (full-thickness nuclear stratification, vesicular nuclei with prominent nucleoli and brisk mitotic figures) and infiltrative invasion of appendiceal wall |
|                        |                  |      | MACA with peritoneal dissemination | High-grade cytological atypia, destructive invasion of wall of appendix, high cellularity, abundant mitotic figures |
| PSOGI classification 42 | Primary mucinous tumours | Benign lesions | Serrated polyp with or without dysplasia | Tubular architecture with basal parts of crypts showing serration and dilatation. Muscularis mucosae intact |
|                        | Mucinous neoplasms | LAMN | HAMN | Pushing invasion with loss of muscularis mucosae and fibrosis of submucosa. Filiform villi, undulating and flat. Basally orientated nuclei with minimal atypia and rare mitotic figures |

(continued)
| Reference/classification | Stage of disease | Type | Histological nomenclature | Key histological features |
|-------------------------|-----------------|------|---------------------------|---------------------------|
| 8th edition AJCC<sup>11</sup> | Primary lesions | Benign lesions | Adenoma | LAMN confined to mucosa with intact muscularis mucosae |
|                         |                 | Premalignant lesions | High-grade dysplasia | Neoplastic cells confined to crypts that do not invade lamina propria |
|                         |                 | Intramucosal adenocarcinoma | | Neoplastic cells invade lamina propria with or without extension into, but not through, muscularis mucosae. pTis. |
|                         |                 | Mucinous appendiceal neoplasms | LAMN | Neoplastic cells extend through wall of appendix with a pushing front, without features of invasion |
|                         |                 |                          | Tis (LAMN): LAMN confined by muscularis propria, acellular mucin or mucinous epithelium may extend into muscularis propria | pT3: involvement of subserosa | pT4a: involvement of visceral peritoneum (with acellular mucin or mucinous epithelium) | pT4b: direct involvement of adjacent organs or structures |
|                         |                 |                              | | HAMN | Tumours with architectural features of LAMN with areas of high-grade dysplasia. pT categorization follows that of mucinous adenocarcinoma |
|                         |                 |                              | Mucinous adenocarcinoma | Neoplastic epithelium displays infiltrative and destructive growth into wall of appendix, beyond muscularis mucosae. Associated desmoplastic reaction | pT1: involvement of submucosa through muscularis mucosa |

(continued)
WHO Classification of Tumors of the Digestive System\(^{10}\) and the seventh edition of the AJCC Staging Manual\(^{41}\) in 2010 made a distinction between low- and high-grade peritoneal disease. The WHO classified primary appendicular tumours into: LAMN, MACA, SRC carcinoma, and undifferentiated appendicular carcinoma. Peritoneal lesions were divided into low- and high-grade disease. Low-grade disease consisted of scanty or missing cells forming small islands or strands, with low cytological and nuclear atypia, and rare mitoses. High-grade disease was defined by the presence of high-grade atypia with cells organized into strands, islands or cribriform structures, and a higher frequency of mitoses. The presence of SRCs led to classification of a lesion as high grade. However, the WHO still considered PMP to be a pathological diagnosis and a borderline malignant entity.

Carr and co-workers\(^{11}\) attempted to validate the prognostic implications of the two-tiered classification system proposed by the fourth edition of the WHO classification. They described significant differences in OS between low-grade and high-grade PMP (5-year OS 84 and 48 per cent after treatment with CRS/HIPEC; \(P < 0.001\)). However, they argued against the use of the term carcinoma to describe lesions derived from the peritoneal spread of a LAMN, as these lesions did not show conventional histological features of malignancy.

The seventh edition of the AJCC\(^{41}\) separated appendiceal carcinomas from the classification of colorectal carcinomas, and distinguished between mucinous and non-mucinous histological subtypes. They advocated a three-tiered classification system for primary lesions: well differentiated (G1), moderately differentiated (G2), and poorly differentiated (G3) tumours. Histological grade was taken into consideration in the staging of stage IV disease. However, only two histological prognostic groups were recognized: low grade, which included well differentiated (G1) mucinous adenocarcinomas, and high-grade, which consisted of both moderately (G2) and poorly differentiated (G3) mucinous adenocarcinomas. The combination of moderately and poorly differentiated disease into the same prognostic group was not supported by a large retrospective database study\(^{20}\). The outcomes for moderately differentiated and poorly differentiated stage IV mucinous adenocarcinoma were observed to be different, hazard ratios (HRs) compared with the well differentiated counterpart were 1.56 (95 per cent c.i. 1.08 to 2.25) and 5.15 (3.45 to 7.68) respectively.

Consequently, the debate continued about whether a two- or three-tiered classification system should be supported. A large retrospective multi-institutional registry by the PSOGI, in which 2298 patients with PMP of appendiceal origin were analysed, found only two relevant histological groups: low- and high-grade disease. Chua and colleagues\(^{15}\), along with Bradley et al.\(^{10}\), were unable to find differences between DPAM and hybrid groups. On the other hand, two large retrospective studies based on the SEER

---

**Table 2.** (continued)

| Reference/classification | Stage of disease | Type | Histological nomenclature | Key histological features |
|--------------------------|-------------------|------|----------------------------|--------------------------|
| Peritoneal implants      | EIVA              | M1a  |                            | pT2: involvement of muscularis propria |
|                          |                   | M1bG1|                            | pT3: involvement of subserosa or meso-appendix |
|                          |                   |      |                            | pT4a: involvement of visceral peritoneum (with acellular mucin or mucinous epithelium) |
|                          |                   |      |                            | pT4b: direct involvement of adjacent organs or structures |
|                          | EIVB              | M1bG2|                            | Intra-peritoneal dissemination containing tumour cells with low-grade cytological atypia without SRCs. Low cellularity (<20%). No infiltrative invasion of peritoneum, may be involved with pushing front without desmoplastic reaction. Perineural or lymphovascular invasion rarely observed |
|                          |                   | M1bG3|                            | Intra-peritoneal dissemination containing tumour cells with mixture of low- and high-grade cytological atypia without SRCs. High cellularity (>20%). Infiltrative invasion of peritoneum and into adjacent organs. Perineural or lymphovascular invasion may be present |

SRC, signet ring cell; DPAM, disseminated peritoneal adenomucinosis; PMCA, peritoneal mucinous carcinomatosis; PMCA-I/D, peritoneal mucinous carcinomatosis with intermediate/disconcordant features; PMCA, peritoneal mucinous carcinomatosis; LAMN, low-grade appendiceal mucinous neoplasm; MACA, mucinous adenocarcinoma of appendix; HAMN, high-grade appendiceal mucinous neoplasm; LG-PMP, low-grade pseudomyxoma peritonei; HG-PMP, high-grade pseudomyxoma peritonei/mucinous carcinomatosis peritonei.
database\textsuperscript{20} and National Cancer Database (NCDB)\textsuperscript{27} identified three histological prognostic groups. Overman and colleagues\textsuperscript{20} analysed 1375 appendiceal mucinous adenocarcinomas and found that histological grade was the strongest predictor of survival in patients with PD. The differences in overall cancer-specific survival across the three-tiered grade classification system were statistically significant. Asare and co-workers\textsuperscript{27}, in an analysis of 11 871 appendiceal carcinomas, of which 5971 were mucinous, also supported a three-tiered grading scheme (well, moderately, and poorly differentiated).

Nonetheless, in 2014, Davison et al\textsuperscript{22} facilitated staging by defining how to grade tumours in their revised staging of 151 patients with PD. They found destructive invasion, high cytological grade, high tumour cellularity, angiolymphatic invasion, perineural invasion, and SRCs to be associated with worse OS in univariable analysis. SRCs had to be invasive and represent at least 10 per cent of the tumour cellularity. AJCC grade G1 was reserved for cases without adverse histological features; AJCC grade G2 for those with at least one adverse feature excluding SRCs, which were representative of AJCC grade G3. Patients with grade G2 and G3 had a 2.7- and 5.1-fold increased risk of death respectively compared with patients with G1 disease. Therefore, a three-tiered grading system was supported. Similar results were obtained by Shetty and colleagues\textsuperscript{21} in an analysis of 211 cases of PMP of appendiceal origin. They developed a three-tiered histological grading system comprising PMP 1, PMP 2, and PMP 3. PMP 1 included patients with copious mucin and scant columnar epithelium without dysplasia, whereas PMP 3 was defined by any SRC component, and PMP 2 by all other in characteristics being glandular mucin; M1b, peritoneal implants containing tumour cells; and M1c, metastasis to sites other than the peritoneum. The G category was subdivided into three relevant prognostic groups based on cytological features, tumour cellularity, and presence of SRCs. G1 corresponded to a well differentiated adenocarcinoma with low-grade cytological atypia, low cellularity (less 20 per cent) without invasion or SRCs. G2 was defined by a moderately differentiated mucinous adenocarcinoma with a component of high cytological atypia, and higher cellularity (over 20 per cent) without SRCs. Finally, G3 referred to a poorly differentiated adenocarcinoma defined by any component of SRCs. The final classification into the prognostic IVA, IVB or IVc stages relied on T and M categories. IVA was defined by M1a (acellular mucin) or M1b G1 (low-grade atypia); IVB by M1b G2 (high-grade atypia) or G3 (high-grade atypia with any component of SRCs); and IVc by M1c (distant metastases to sites other than the peritoneum) (Table 2).

Other histopathological landmarks

**Acellular mucin**

Pai and colleagues\textsuperscript{17} observed that only 1 of 14 patients with acellular intraperitoneal disease developed recurrence after 45 months. The presence of acellular/acellular peritoneal disease mucin was associated with OS in multivariable analysis. Furthermore, Davison and co-workers\textsuperscript{22} noted that 7 per cent of patients in the subgroup with low-grade mucinous neoplasms had acellular mucinous deposits and none of them developed recurrence. These results suggest that patients with acellular disease have a much lower risk of disease recurrence and improved OS compared with those with low-grade cellular disease.

**Signet ring cells**

The presence of SRCs has been a matter of debate. In 1995, Ronnett and colleagues\textsuperscript{7} had allowed SRCs to be present in the PMCA-D group, whereas Bradley et al.\textsuperscript{10} considered them to be...
inherent to high-grade lesions. In 2014, Sirintrapun and co-workers studied the significance of SRCs in 55 patients with MACA and PD. None of the 11 patients with low-grade adenocarcinoma had SRCs, whereas 29 of the 44 in the high-grade adenocarcinoma group presented with SRCs. The presence of SRCs could be divided into two prognostically significant groups: SRCs floating in mucin pools or tissue-invading SRCs. The 5-year OS for patients with high-grade mucinous adenocarcinoma without SRCs was similar to that of patients with high-grade mucinous adenocarcinoma with SRCs in mucin pools (32 versus 36 per cent respectively; \( P = 0.58 \)). The presence of SRCs invading tissues decreased OS to a median of 0.5 years, compared with 2.9 and 2.4 years for mucinous adenocarcinoma without SRCs (\( P = 0.003 \)) and mucinous adenocarcinoma with floating SRCs (\( P = 0.004 \)). Mucinous adenocarcinoma with SRCs invading tissues had a higher rate of incomplete cytoreductions. It was suggested that their presence could be a potential contraindication to treatment with CRS/HIPEC.

Qualitative analysis of literature review

The most commonly used classification system was Ronnett’s (9 studies). However, increasing use of PSOGI (6 studies) and AJCC (7) classifications over time was noted. Nine studies supported a two-tiered, 12 a three-tiered, and two a four-tiered classification system.

Of studies that used Ronnett’s classification system, six identified only two prognostically relevant groups in the multivariable analysis, or had no PMCA-I/D group. Three studies grouped PMCA-I and PMCA, whereas the other two grouped DPAM and PMCA-I.

Three studies demonstrated that acellular mucin was associated with better DFS than LG-PMP in the PSOGI classification; however, a fourth study failed to find significant differences. Additionally, in multivariable analysis, four studies associated the presence of SRCs with worse OS compared with HG-PMP in the PSOGI classification and M1bG2 in the eighth edition of the AJCC classification.

The results of the studies included are summarized in Table 1.

Discussion

The diagnostic terminology for appendicular mucinous tumours has evolved based on the acquisition of pathological insights. However, a common language is necessary to aid therapeutic decision-making and design of clinical trials. Much debate remains despite the enormous efforts of pathologists and institutions (WHO, AJCC) in the development of classification systems with prognostic implications.

The eighth edition of the AJCC classification has captured the peculiarities of mucinous tumours of the appendix. However, only two prognostic groups (EIVA and EVIB) were distinguished. The literature suggests that M1a has a lower risk of recurrence than M1bG1,2,23,44. Reghunathan and colleagues observed that only one in 33 patients with M1a disease developed recurrence, with 13 having DFS of more than 3 years (HR 9.8; \( P = 0.025 \)). Additionally, Choudry et al. found that acellular mucin (19 patients) and scant cellularity (less than 2 per cent of epithelial cells) (30 patients) were associated with better DFS than moderate cellularity (2–19 per cent of epithelial cells) (242 patients) with a HR of 4.4 (\( P = 0.002 \)). Regarding stage EVIB, the authors of single-centre retrospective studies have argued that patients with M1bG2 disease have worse OS than those with M1bG2 disease. Ihemelandu and colleagues observed a decrease in median OS from 45.4 months in patients with moderate-high-grade histology to 18.9 months in patients with SRMs, with a HR of 1.4 (\( P < 0.001 \)). Munoz-Zuluaga et al. reported median OS of 90 months for patients with high-grade mucinous carcinoma peritonei versus 26.4 months for those with high-grade Mucinous Carcinoma Peritonei with Signet Ring Cells (MCP-S), with a HR of 2.9 (\( P < 0.001 \)). Multicentre studies based on large databases observed similar results: 16.2 (ref. 38) and 32 (ref. 39) months. However, these results must be interpreted cautiously as specific pathologic criteria such as acellular mucin and SRCs are not registered routinely in large databases. Furthermore, pathological discordance between G2 and G3 grades has been recorded owing to ‘degenerative cells within pools of mucin that mimic SRC’, which in the hands of inexperienced pathologists may erroneously lead to disease being classified as G3. In G3, SRCs should be infiltrating and represent more than 10 per cent of the tumour’s cellularity. Therefore, concrete histological criteria should be set to define this entity, with both the relative percentage of tumour cells and their arrangement taken into consideration.

The prognostic impact of the four-tiered PSOGI classification has been evaluated by two groups recently. In 2017, Huang et al. observed that median OS was not reached in acellular mucin and LG-PMP groups; it was 58.2 months in groups with HG-PMP and 31.1 months in HG-PMP with SRCs (HR 3.13; \( P < 0.001 \)). However, in 2018, Baratti and colleagues found that the two-tiered WHO classification (HR 1.48; \( P = 0.028 \)) correlated better with OS than the PSOGI classification (HR 1.22; \( P = 0.149 \)). They pointed out that having more categories decreases the number of patients in each, which reduces statistical power.

The main limitation of this review is that it is based on retrospective studies, so evidence supporting the PSOGI classification is limited. Publication bias should also be considered as hand-picked studies7,9,13 that did not fully meet the inclusion criteria were included and the 100-patient limit was met by most historically relevant studies. However, publications by Ronnett and colleagues, which provided the first histological classification, and Misdraji et al., which introduced LAMM into the literature, could not be excluded and setting a patient limit is essential to facilitate the selection process. Furthermore, comparison of modern studies using recent classification systems with older literature is difficult, despite detailed histological descriptions.

The standard treatment option for mucinous appendiceal tumours with PD is CRS/HIPEC. However, this aggressive treatment strategy is associated with high morbidity and mortality rates, so patients must be selected carefully. There is enough evidence in the literature to argue in favour of the four-tiered PSOGI classification system. However, another international consensus should take place in order to propose a unified classification system. There is great need for a common language to fully convey and understand the prognostic significance, and develop management protocols for this disease.

Acknowledgements

No preregistration exists for the studies reported in this article.

Disclosure. L. Martín-Román declares that she has no conflict of interest. P. Lozano declares that he has no conflict of interest. W. Vásquez declares that he has no conflict of interest. N. Palencia declares that she has no conflict of interest. Y. Gómez declares
that she has no conflict of interest. M. J. Fernández-Aceñero declares that she has no conflict of interest. L. González-Bayón declares that he has no conflict of interest.

**Supplementary material**

Supplementary material is available at BJS Open online.

**References**

1. McCusker ME, Coté TR, Clegg LX, Sohin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973–1998. Cancer 2002; 94: 3307–3312
2. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7970 appendectomy specimens. Dis Colon Rectum 1994; 38: 75–80
3. Turaga KK, Pappas SG, Gamblin TC. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012; 19: 1379–1385
4. McGorry ML, Maggard MA, Kang H, O’Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum 2005; 48: 2264–2271
5. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg 1994; 219: 109–111
6. Carr NJ, McCarthy WF, Sohin LH. Epithelial noncarcinoid tumors and tumor-like lesions of the appendix. A clinicopathologic study of 184 patients with a multivariate analysis of prognostic factors. Cancer 1995; 75: 757–768
7. Ronnett BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to ‘pseudomyxoma peritonei’. Am J Surg Pathol 1995; 19: 1390–1408
8. Ronnett BM, Yan H, Kurman RJ, Shmookler BM, Wu L, Sugarbaker PH. Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis. Cancer 2001; 92: 85–91
9. Misdraji J, Yantiss RK, Graeme-Cook FM, Balis UJ, Young RH. Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases. Am J Surg Pathol 2003; 27: 1089–1103
10. Bradley RF, Stewart JH, Russell GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006; 30: 551–559
11. Carr NJ, Finch J, Ilesley IC, Chandrakumaran K, Mohamed F, Mirnezami A et al. Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases. J Clin Pathol 2012; 65: 919–923
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
13. Sirintrapan SJ, Blackham AU, Russell G, Votanopoulos K, Stewart JH, Shen P et al. Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol 2014; 45: 1597–1604
14. Stewart JH, Shen P, Russell CB, Bradley RF, Hundleby JC, Loggie BL et al. Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol 2006; 13: 624–634
15. Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2007; 14: 104–109
16. Elias D, Honoré C, Ciuchendréa R, Billard V, Raynard B, Dico RL et al. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Br J Surg 2008; 95: 1164–1171
17. Pai RK, Beck AH, Norton JA, Longacre TA. Appendiceal mucinous neoplasms: clinicopathologic study of 116 cases with analysis of factors predicting recurrence. Am J Surg Pathol 2009; 33: 1425–1439
18. Elias D, Gilly F, Quenet F, Bereder JM, Sidérios L, Mansvelt B et al.; Association Française de Chirurgie. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol 2010; 36: 456–462
19. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 2012; 30: 2449–2456
20. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R et al. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg 2013; 257: 1072–1078
21. Shetty S, Natarajan B, Thomas P, Govindarajan V, Sharma P, Loggie B. Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival. Am Surg 2013; 79: 1171–1176
22. Davison JM, Choudry HA, Pangpank JF, Ahrendt SA, Holtzman MP, Zureikat AH et al. Clinicopathologic and molecular analysis of disseminated appendiceal mucinous neoplasms: identification of factors predicting survival and proposed criteria for a three-tiered assessment of tumor grade. Mod Pathol 2014; 27: 1521–1539
23. Jimenez W, Sardi A, Nieroda C, Sittig M, Milovanov V, Nunez M et al. Predictive and prognostic survival factors in peritoneal pseudomyxomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2014; 21: 4218–4225
24. Shaib WL, Martin LK, Choi M, Chen Z, Krishna K, Kim S et al. Hyperthermic intraperitoneal chemotherapy following cytoreductive surgery improves outcome in patients with primary appendiceal mucinous adenocarcinoma: a pooled analysis from three tertiary care centers. Oncologist 2015; 20: 907–914
25. Iheemelandu C, Sugarbaker PH. Clinicopathologic and prognostic features in patients with peritoneal metastases from mucinous adenocarcinoma, adenocarcinoma with signet ring cells, and adenocarcinoid of the appendix treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2016; 23: 1474–1480
26. Milovanov V, Sardi A, Studeman K, Nieroda C, Sittig M, Gushchin V. The 7th edition of the AJCC staging classification correlates with biologic behavior of mucinous appendiceal tumor with peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Ann Surg Oncol 2016; 23: 1928–1933
27. Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S et al. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: analysis of the National Cancer Data Base. Cancer 2016; 122: 213–221
28. Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA et al. Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. J Gastrointest Oncol 2017;9:354–362
29. Huang Y, Alzahrani NA, Chua TC, Morris DL. Histological sub-type remains a significant prognostic factor for survival outcomes in patients with appendiceal mucinous neoplasm with peritoneal dissemination. Dis Colon Rectum 2017;60:360–367
30. Reghunathan M, Kelly KJ, Valasek MA, Lowy AM, Baumgartner JM. Histologic predictors of recurrence in mucinous appendiceal tumors with peritoneal dissemination after HIPEC. Ann Surg Oncol 2018;25:702–708
31. Baratti D, Kusamura S, Milione M, Bruno F, Guaglio M, Deraco M. Validation of the recent PSOGI pathological classification of pseudomyxoma peritonei in a single-center series of 265 patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2018;25:404–413
32. Choudry HA, Pai RK, Shuai Y, Ramalingam L, Jones HL, Pingpank JF et al. Impact of cellularity on oncologic outcomes following cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for pseudomyxoma peritonei. Ann Surg Oncol 2018;25:76–82
33. Munoz-Zuluaga C, Sardi A, King MC, Nieroda C, Sittig M, MacDonald R et al. Outcomes in peritoneal dissemination from signet ring cell carcinoma of the appendix treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2019;26:473–481
34. van Eden WJ, Kok NF, Mælandrum L, Jøngevik K, Woensdregt K, Bottenberg PD et al. Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms. BJS Open 2019;3:376–386
35. Masckau-Dahn D, Trabulsi N, Dubé P, Aubé-Lecompte ME, Cloutier AS, Mitchell A et al. Long term survival analysis after hyperthermic intraperitoneal chemotherapy with oxaliplatin as a treatment for appendiceal peritoneal carcinomatosis. Surg Oncol 2019;28:69–75
36. Narasimhan V, Pham T, Warrier S, Craig Lynch A, Michael M, Tie J et al. Outcomes from cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal epithelial neoplasms. ANZ J Surg 2019;89:1035–1040
37. Solomon D, Bekhor E, Leigh N, Maniar YM, Totin I, Hofstedt M et al. Surveillance of low-grade appendiceal mucinous neoplasms with peritoneal metastases after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: are 5 years enough? A multisite experience. Ann Surg Oncol 2020;27:147–153
38. Legué LM, van Erning FN, Creemers GJ, de Hingh IJHT, Lemmens VEPP, Huysentruyt CJ. The prognostic relevance of histologic subtype in appendiceal adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol 2020;46:433–438
39. Levinsky NC, Morris MC, Wima K, Sussman JJ, Ahmad SA, Floyd JM et al. Should we be doing cytoreductive surgery with hipec for signet ring cell appendiceal adenocarcinoma? A study from the US HIPEC Collaborative. J Gastrointest Surg 2020;24:155–164
40. Carr NJ, Sobin LH. Adenocarcinoma of the appendix. In: FT Bosman, F Carneiro, RH Hruban, ND Theise (eds), WHO Classification of Tumors of the Digestive System. Lyon: IARC Press, 2010, 122–125
41. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene F, Troisi R (eds). AJCC Cancer Staging Handbook (7th edn). New York: Springer, 2010
42. Carr NJ, Cecil TD, Mohamed F, Sobin LH, Sugarbaker PH, González-Moreno S et al.; Peritoneal Surface Oncology Group International. A consensus for classification and pathologic reporting of pseudomyxoma peritonei and associated appendiceal neoplasia: the results of the Peritoneal Surface Oncology Group International (PSOGI) modified Delphi process. Am J Surg Pathol 2016;40:14–26
43. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more ‘personalized’ approach to cancer staging. CA Cancer J Clin 2017;67:93–99
44. Valasek MA, Pai RK. An update on the diagnosis, grading, and staging of appendiceal mucinous neoplasms. Adv Anat Pathol 2018;25:38–60
45. Govaerts K, Lurvink RJ, De Hl, Van der Speeten K, Villeneuve L, Kusamura S et al. Appendiceal tumours and pseudomyxoma peritonei: literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment. Eur J Surg Oncol 2021;47:11–35
46. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76